Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
December 2025—The absence of CDC surveillance data due to the government shutdown has created uncertainty about the severity and impact of the current respiratory virus season. While regional public health surveillance provides some insights, concerns remain about the potential for a severe season, exacerbated by vaccine hesitancy and changes in vaccine guidance.
December 2025—Northwestern Medicine Delnor Hospital piloted a program using drones for transporting patient samples and blood products between the hospital and cancer center. The program, using Valqari drones, achieved a 100% success rate in delivering 303 packages without any damage or temperature fluctuations.
December 2025—Massachusetts General Hospital implemented a clinical decision support solution to reduce unnecessary CBC and differential orders, particularly for inpatients. The solution involved an interruptive alert that targeted daily, more than daily, and as-needed orders, recommending alternative orders like CBCs without differentials.
December 2025—A 21-year-old male with a history of acute promyelocytic leukemia (APL) presented with symptoms suggestive of relapse. While standard tests like qRT-PCR and amplicon-based sequencing failed to detect the PML::RARA fusion, AMP NGS revealed an atypical bcr2 transcript with a novel breakpoint.
December 2025—A roundtable discussion on laboratory information systems (LIS) focused on the application of AI in lab workflows. Participants emphasized the need for AI to be used as a targeted tool to augment human work, highlighting its potential in streamlining documentation, coding, and data extraction.
November 2025—Laboratories considering AI-driven workflows should first identify the specific problem they aim to solve and assess if simpler coding solutions are sufficient. While out-of-the-box AI solutions from vendors offer a lower barrier to entry, laboratories must ensure these solutions align with their workflows and validate them in their own environments.
November 2025—Two new ADLM documents provide guidance on toxicology testing for emergency departments, replacing a 2003 guideline. The documents address test menus, turnaround times, and the importance of educating ED staff on assay limitations.
November 2025—A recent article in Archives of Pathology & Laboratory Medicine emphasizes the importance of gender-inclusive care in cytopathology laboratories. The authors, members of the CAP Cytopathology Committee, identify four key areas for improvement: laboratory information systems and terminology, cervicovaginal Pap test screening, HPV testing, and anal Pap test screening. They advocate for gender-inclusive data entry, understanding changes from hormonal therapy, equitable access to HPV testing, and expanding anal Pap test screening infrastructure.
November 2025—A 24-year-old female with hereditary stomatocytosis presented with a critical potassium concentration of 7.9 mmol/L. Despite ruling out common causes like hemolysis and EDTA contamination, the elevated potassium persisted, leading to a diagnosis of a PIEZ01 mutation causing potassium leakage.
November 2025—The Color Atlas of Body Fluids: An Illustrated Field Guide Based on Proficiency Testing, second edition, features over 1,200 photographs, 70 photo galleries, 360 illustrations, and 15 videos. The atlas, which completes the CAP’s Color Atlas series, uses images from CAP’s laboratory proficiency testing, providing authenticity and real-world variability.
